Neonatal Care
Eat Sleep Console
The Eat Sleep Console (ESC) Model of Care in Obstetric and Neonatal Units across Manitoba standardizes evidence-informed care for newborns exposed to substances and their families to improve health outcomes and the patient/family experience.
A phased implementation is planned for the ESC Model of Care, with HSC, and Women’s Hospital Obstetric and Neonatal Units being implemented in Spring of 2025. Provincial Obstetric and Neonatal sites will be added later at collaboratively determined intervals.
Provincial Clinical Communication: Eat Sleep Console (ESC) Model of Care in Manitoba
Provincial Clinical Guidelines
- Provincial Clinical Guideline – Eat Sleep Console
- Provincial Clinical Guideline – Substance Use & Breastfeeding
Clinical Documents
- Eat Sleep Console (ESC) Assessment Tool
- Eat Sleep Console (ESC) Standard Orders on Postpartum Units
- Eat Sleep Console (ESC) Standard Escalation Orders for NICUs
- Eat Sleep Console (ESC) Standard Weaning Orders for NICUs
Additional Resources
RSV Immunoprophylaxis Program Expansion
Program Overview
Effective Oct. 1, 2025, Manitoba is expanding its Respiratory Syncytial Virus (RSV) immunoprophylaxis program to include all infants born between October 1, 2025, and March 31, 2026. Eligible infants will receive a single dose of nirsevimab (Beyfortus™), a long-acting monoclonal antibody that provides immediate passive immunity against RSV.
The primary goal is in-hospital administration to eligible infants in Obstetrical Units prior to discharge. Public Health Nursing will address infants who do not receive the dose before discharge.
The current Manitoba High-Risk RSV Immunoprophylaxis Program for infants and children with high-risk conditions continues to be led by Dr. Aaron Chiu. Eligibility for these infants will be determined on a case-by-case basis by them with specialist consultation as needed. Please see contact information below.
Healthcare Providers
Pediatricians, midwives and family physicians are responsible for obtaining consent and ordering the antibody during hospitalization in the obstetrical units. Doses will not be available in outpatient practices except for Public Health nursing and midwifery clinics.
Resources
Pharmacy
Pharmacy teams will order the antibody directly from the provincial vaccine warehouse using Manitoba Health Vaccines and Biologics Order Form. Initial orders should occur now, with a second provincial order planned for October.
Resources
Nursing Staff
Nursing staff will administer the dose post-consent and document the administration on the MAR, discharge paperwork, postpartum referral, and the new RSV Monoclonal Antibody Administration Reporting Form.
Please note: Public Health plans reporting form into the postpartum referral in the future to reduce the amount of documentation required.
Resources
- RSV Monoclonal Antibody Administration Reporting Form for Health Care Providers
- RSV Immunoprophylaxis Program Expansion Nursing Training Program
- Nirsevimab WRHA/HSC Monograph
- Manitoba Health RSV Site
- Manitoba Paediatric RSV Immunoprophylaxis Program and Administration Pathways
- Nirsevimab Quick Reference Guide
- Nirsevimab (RSV Antibody) Public Factsheet
- BEYFORTUS™ – Nirsevimab Injection Product Monograph
Midwifery
Midwives will offer and receive consent prior to their administration of the RSV antibody, nirsevimab, for newborns under their care delivered both in-hospital and out-of-hospital settings. Midwives must report to Public Health as well as complete the same documentation process noted in the nursing staff section. Please review the RSV Immunoprophylaxis Program Expansion Training for clarity of the midwifery process.
Resources
- RSV Monoclonal Antibody Administration Reporting Form for Health Care Providers
- RSV Immunoprophylaxis Program Expansion Midwifery Training
- Nirsevimab WRHA/HSC Monograph
- Manitoba Health RSV Site
- Manitoba Paediatric RSV Immunoprophylaxis Program and Administration Pathways
- Nirsevimab Quick Reference Guide
Family Engagement
Families will be informed through Public Health campaigns and health care providers.
Resources
Support
If there are any questions or further implementation support required, please contact Angela Matwick, Provincial Director of the Women and Children Provincial Clinical Program and/or Dr. Aaron Chiu of the Manitoba High-Risk RSV Immunoprophylaxis Program [email protected].
Thank you for your continued collaboration in supporting the health of Manitoba’s infants. Your efforts are essential to the successful implementation of this expanded RSV immunoprophylaxis program.